Claudin-3:银屑病患者肠道完整性新标志物,与疾病严重度相关
横断面研究纳入60例银屑病患者与30例年龄、性别及BMI匹配的健康对照,检测血浆Claudin-3浓度。患者组Claudin-3显著高于对照,且与PASI评分、中性粒细胞/淋巴细胞比值及活动性吸烟独立相关。Claudin-3或可作为反映银屑病肠道屏障完整性与疾病严重度的生物标志物。
要点
- 银屑病患者血浆Claudin-3显著高于健康对照。
- Claudin-3与PASI评分及中性粒细胞/淋巴细胞比值正相关。
- 活动性吸烟与Claudin-3浓度独立相关。
核心结论
- Claudin-3作为肠道通透性生物标志物在银屑病患者中升高,并与疾病严重度和吸烟相关。
- 尚需进一步研究明确强化肠道屏障是否可作为银屑病新治疗靶点。
研究设计与样本
- 横断面研究纳入60例银屑病患者(39男21女,平均年龄45.6±12.1岁)和30例健康对照(18男12女,平均年龄46.3±15.5岁),年龄、性别及BMI匹配。
- 采用酶联免疫吸附试验测定血浆Claudin-3浓度。
主要发现
- 银屑病患者血浆Claudin-3中位数(四分位距)为50.7 ng/mL(47.3-54.2),显著高于健康对照的43.3 ng/mL(42.3-44.2),P < 0.001。
- 治疗16周后达到ΔPASI90应答的患者,循环Claudin-3血浆浓度呈下降趋势。
- Claudin-3浓度与PASI评分正相关(r = 0.828;P < 0.001),与中性粒细胞/淋巴细胞比值正相关(r = 0.847;P < 0.001)。
- 多变量线性回归分析证实Claudin-3与PASI评分(P < 0.001)、中性粒细胞/淋巴细胞比值(P < 0.01)及活动性吸烟(P < 0.05)相关。
临床怎么用
- Claudin-3可作为评估银屑病患者肠道屏障完整性的循环标志物。
- 监测Claudin-3可能有助于反映疾病严重度及吸烟对银屑病的影响。
局限性
- 为横断面研究,无法确定因果关系。
- 样本量有限(60例患者和30例对照)。
- ΔPASI90应答后Claudin-3下降仅为趋势,未报告统计学显著性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Gut dysbiosis and increased intestinal permeability play a significant role in the pathogenesis of psoriasis and its comorbidities. Claudin-3 is a key component of tight junctions, which may serve as marker of gut barrier integrity. OBJECTIVES: The aim of the study was to investigate circulating plasma claudin-3 in patients with psoriasis and to evaluate clinical and metabolic factors, which determine its concentration. METHODS: This cross-sectional study included 60 patients with psoriasis (39 men and 21 women, mean age: 45.6 ± 12.1 years) and 30 healthy controls (18 men and 12 women, mean age: 46.3 ± 15.5 years) age, sex and body mass index-matched. Plasma claudin-3 concentration was measured using an enzyme-linked immunosorbent assay. RESULTS: Plasma claudin-3 concentration was significantly higher in patients with psoriasis in comparison with healthy control [median (interquartile range), 50.7 ng/mL (47.3-54.2) vs. 43.3 ng/mL (42.3-44.2), P < 0.001]. Patients who achieved ΔPASI90 response after 16 weeks of treatment showed tendency to decrease in circulating claudin-3 plasma concentration. Positive correlations between claudin-3 concentration and the PASI score (r = 0.828; P < 0.001) as well as claudin-3 and neutrophil-to-lymphocyte ratio (r = 0.847; P < 0.001) were found. A multivariable linear regression analysis confirmed association of claudin-3 with the PASI score (P < 0.001), neutrophil-to-lymphocyte ratio (P < 0.01) and active smoking (P < 0.05). CONCLUSION: Claudin-3, a biomarker for gut permeability, is increased in psoriasis and correlates with disease severity and smoking. Further investigations are needed to determine whether reinforcing intestinal barrier may be a new therapeutic target in psoriasis.
引用
- Sikora M, Chrabąszcz M, Waśkiel-Burnat A, et al. Claudin-3 - a new intestinal integrity marker in patients with psoriasis: association with disease severity. J Eur Acad Dermatol Venereol. 2019. PMID: 31120609. doi:10.1111/jdv.15700
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。